Yeah, it's fascinating stuff. This was published with the Japanese Society of Anti -Aging Medicine.

Okay, so, you know, most people hear psilocybin and they immediately think mental health, right? Depression, anxiety, addiction, maybe even Alzheimer's research.

Definitely. The effects can be profound, sometimes even from like a single dose, but the how, the actual molecular nuts and bolts behind those benefits, especially outside the brain, has been a bit of a black box.

So this new study kind of steps back and asks a, well, a much wider question. They introduced this idea called the psilocybin telomere hypothesis.

Precisely. Think of them like the little plastic ticks on shoelaces. They protect the important stuff, your DNA. Every time a cell divides, they get a bit shorter. Eventually, they get too short and the cell stops dividing. It goes into senescence. That's, you know, a key part of aging at the cellular level.

It does, but here's the link they explored. We know our mental state can influence telomere length. Things like chronic stress, anxiety, depression, they're associated with faster telomere shortening.

Kind of, yeah. And conversely, positive mental states seem to correlate with longer telomeres. So the researchers thought, well, psilocybin seems pretty good at improving those negative states. Right.

Okay, so from mood improvement to actually changing the aging clock in our cells, that's ambitious. How did they even start to test that?

Psilocin.

Got it. So testing the active compound, what happened in those human cells?

Extended lifespan. Like, they just kept dividing longer.

How much longer are we talking? Like, a little bit, or?

Yeah. And even in the adult skin cells, the 100 micromolar dose gave a 51 percent boost.

They saw a whole shift. Psilocin basically delayed the cells from hitting that wall, you know, replicative senescence. They divided more times overall. That's the cumulative population doublings. And they divided faster, or rather, the time it took them to double decreased.

That's a good way to put it. And when they looked at the molecular markers, it backed this up.

They saw less of the stuff you associate with aging cells, like lower beta -galactosidase activity. That's a common aging marker. And lower levels of proteins that stop cell division, like P21 and P16.

Right. And at the same time, more go signals, more markers of proliferation, like PCNA. It really looked like the cells were, well, more youthful.

Yes, and this is a big one. They found elevated SIRT1.

Exactly. It's like a master regulator for cellular health and resilience. Seeing SIRT1 go up is a really important clue connecting psilocin to these anti -aging effects.

They looked at that too. And they found significantly less oxidative stress. And it was dose -dependent, more psilocin, less stress.

It seems linked to lower levels of Nox4. That's an enzyme that generates damaging oxidants and higher levels of Nrf2. Nrf2 is basically the master switch for the cell's antioxidant defenses.

You'd think so, yeah. Less DNA damage, better overall protection.

They did, and this was crucial. They compared psilocin -treated cells with untreated cells of the same age that had become senescent. And the telomeres in the treated cells were preserved. They were longer.

It's the first experimental evidence backing that psilocybin -telomere hypothesis, a direct link observed in the lab. Pretty significant.

Right, the essential next step. So they moved to in vivo studies using mice, aged female mice specifically. They were 19 months old.

Older, roughly equivalent to maybe 60, 65 years old in human terms, so definitely getting up there.

They gave them psilocybin, once a month for 10 months.

The survival results were, well, quite stark. The mice that got psilocybin had an 80 % survival rate over that period.

Only 50 % survived.

It really is a very significant increase in lifespan for these aged mice.

Yes. They mentioned phenotypic improvements. Basically, the psilocybin mice looked healthier. Better fur quality, more hair growth, less white hair, visible signs that they were aging better.

Seems that way. It points towards a systemic effect, not just something hidden away inside the cells.

The study suggests psilocybin is hitting signaling pathways tied directly to cellular aging. It's delaying that senescence, boosting lifespan. And they point towards the 5-HT2A receptor.

It is. But here's the key. That receptor isn't only in the brain. It's found in lots of other cell types throughout the body.

And previous research has actually shown that activating this receptor can boost SIRT1 expression and antioxidant enzymes, which, you know, fits perfectly with what they saw here. Elevated SIRT1 and reduced oxidative stress.

That seems to be the leading idea. It's a really neat connection between the known neurological target and these newly discovered systemic aging effects.

And you know, that's exactly the kind of thing that makes this field so exciting. It deepens our whole understanding. It's actually why the team at RevGenetics focuses on researching unique compounds like fisetin, tetrahydrocurcumin, and resveratrol. They've been doing that since 2007. It's exciting to see studies like this discovering more about how nature's medicine cabinet is just so vast. You know, so much potential for health and longevity still being uncovered.

Okay, so stepping back. This is pretty groundbreaking, isn't it? You said it's the first experimental evidence showing psilocybin hitting multiple hallmarks of aging.

So what could this mean down the line for, you know, aging research or even therapies?

eruptive meaning.

It really does. Because often you wonder if you need to start interventions super early. This suggests maybe not. Maybe there's benefit even later on.

Well, thinking about safety, there was that clinical trial where people up to 70 years old took psilocybin with no serious issues. And the FDA has given it that breakthrough therapy status, which suggests a decent safety profile. So yeah, it looks potentially feasible.

Oh, absolutely. The study authors are very clear about that. We need more research to figure out the best way to use it. What's the optimal dose? How often? When should treatment start? Would earlier be even better? Lots of practical questions remain.

That's another key point. This mouse study only used females just to keep things simpler initially. But we definitely need studies looking at males too to see if the effects are the same or different. Biological sex can matter a lot in how therapies work.

That's a really important consideration. And the researchers highlight it. Their cell studies didn't show any signs of the cells turning cancerous, which is good.

But they strongly emphasize the need for long -term studies in animals specifically looking at cancer risk. If you suppress a natural anti -cancer mechanism like senescence over the long term, you absolutely have to rigorously check if that has any unintended consequences regarding cancer. It's a critical safety check needed for sure.

Not completely. We need more work to pin down exactly how it's all happening. Is it all through that 5 -HT2A receptor or are there other pathways involved? And what about epigenetics? Things like chromatin changes or DNA methylation, these can alter gene activity without changing the DNA code itself. They might play a role too. Still more digging to do there.

Unfortunately, yes. The paper mentions the ongoing challenges. Psilocybin is still a scheduleized substance in many places, which makes research complicated and expensive. And getting federal funding for this kind of work has been historically difficult. These are real -world barriers that can slow down progress.

I'd say so. Very optimistic, but grounded. These are early results, yes, but they're incredibly exciting. They genuinely open up a whole new way of thinking about psilocybin and its potential impact, stretching way beyond the mind and into the fundamental processes of aging itself.

Absolutely. And if you want to learn more about their mission and the science they explore, you can visit RevGenetics.com.